These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Why did the FDA approve these advertisements? Oaks D PLoS Med; 2006 Feb; 3(2):e117; author reply e116. PubMed ID: 16492081 [No Abstract] [Full Text] [Related]
4. Should industry speak the loudest in informing the public on medical matters? McCarter G PLoS Med; 2006 Feb; 3(2):e118; author reply e116. PubMed ID: 16492082 [No Abstract] [Full Text] [Related]
5. [Ethical problems in the use of SSRI-s]. Szendi G Neuropsychopharmacol Hung; 2005 Dec; 7(4):221. PubMed ID: 16496487 [No Abstract] [Full Text] [Related]
6. Excess marks the spot: the FDA blows the whistle on abuses in new-drug ads. Time; 1982 Sep; 120(13):83. PubMed ID: 10257313 [No Abstract] [Full Text] [Related]
7. Drug makers set off a bitter debate with ads aimed directly at patients. Rosenthal E N Y Times Web; 1991 Mar; ():34. PubMed ID: 11653935 [No Abstract] [Full Text] [Related]
8. Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome. Sclar DA; Robison LM; Castillo LV; Schmidt JM; Bowen KA; Oganov AM; Skaer TL; Kogut SJ Headache; 2012 Feb; 52(2):198-203. PubMed ID: 22289074 [TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical manufacturers likely to be challenged by regulatory agencies over assertions of deceptive advertising. Fine A Exec Solut Healthc Manag; 1999 Jun; 2(6):2-3. PubMed ID: 10538255 [No Abstract] [Full Text] [Related]
10. Examining the FDA's oversight of direct-to-consumer advertising. Gahart MT; Duhamel LM; Dievler A; Price R Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-120-3. PubMed ID: 14527243 [TBL] [Abstract][Full Text] [Related]
12. A new antidepressant. Glazer WM Behav Healthc; 2011 Sep; 31(6):39-40. PubMed ID: 22026116 [No Abstract] [Full Text] [Related]
13. Pharmacogenomics in psychiatry - Clinical innovation utilised by the Therapeutic Goods Administration and Food and Drug Administration. Kulkarni J Aust N Z J Psychiatry; 2017 Jan; 51(1):93-94. PubMed ID: 27609939 [No Abstract] [Full Text] [Related]
14. Medical Marketing in the United States, 1997-2016. Schwartz LM; Woloshin S JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375 [TBL] [Abstract][Full Text] [Related]
15. Vortioxetine (Brintellix) for depression. Med Lett Drugs Ther; 2013 Nov; 55(1430):93-5. PubMed ID: 24276501 [No Abstract] [Full Text] [Related]
18. Fallout from the pharma scandals: the loss of doctors' credibility? Diller L Hastings Cent Rep; 2005; 35(3):28-9. PubMed ID: 16092398 [No Abstract] [Full Text] [Related]
19. Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs. Faerber AE; Kreling DH J Gen Intern Med; 2014 Jan; 29(1):110-8. PubMed ID: 24030427 [TBL] [Abstract][Full Text] [Related]
20. Survey suggesting that prescription drug ads help public is met with skepticism. Mitka M JAMA; 2003 Feb; 289(7):827-8. PubMed ID: 12588246 [No Abstract] [Full Text] [Related] [Next] [New Search]